Two Systemic Barriers Blocking Access to Cutting-Edge Medical Technologies

Medical innovation outpaces medical policy with health insurance plans. That reality can be difficult to accept for companies that have poured significant investment into a new device, drug, or biologic. For health plans, FDA marketing authorization is important, but other factors are essential: long-term data, medical society guidelines, provider utilization, etc. Until those factors are […]